Prostate-specific antigen, risk factors, and prostate cancer: Confounders nestled in an enigma

Journal of the National Cancer Institute

Volumn 102, Issue 17, 2010, Pages 1299-1301

  Thompson, Ian M ^a   Ankerst, Donna P ^a,b   Tangen, Catherine M ^c  

^a University of Texas Health Science Center   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER RISK; EDITORIAL; HEREDITY; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; BLOOD; EARLY DIAGNOSIS; EPIDEMIOLOGY; GENETICS; IMMUNOLOGY; MALE; PROCEDURES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SWEDEN;

CONFOUNDING FACTORS (EPIDEMIOLOGY); EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77956570814     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq313     Document Type: Editorial

References (8)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Ross LE, Taylor YJ, Richardson LC, Howard DL. Patterns of prostate specifc antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006. J Natl Med Assoc. 2009; 101(4):316-324.
3. Seidman H, Mushinski MH, Gelb SK, Silverberg E. Probabilities of eventually developing or dying of cancer\United States, 1985. CA Cancer J Clin. 1985;35(1):36-56.
4. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically signifcant prostate cancer in Black than in White American men and infuences racial progression and mortality disparity. J Urology. 2010;183(5):1792-1797.
5. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specifc antigen level ≤ 4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239-2246.
6. Bratt O, Garmo H, Adolfsson J, et al. Effects of prostate-specifc antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst. 2010; 102:1336-1343.
7. Thompson IM, Ankerst DP, Chi C, et al. The operating characteristics of prostate-specifc antigen in a population with initial PSA of 3.0 ng/mL or lower. JAMA. 2005;294(1):66-70.
8. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-534.